Reports and Filings

MetaBlok and MetaMx Scientists

Lead scientists for MetaBlok™ and MetaMx™

AB569 Principal Scientist

Lead scientist for AB569 which targets Respiratory Pseudomonas Infections

BORG Peptide Solid Surface Interface Scientists

Lead scientists for BORG Peptides

Treatments for Inflammation Scientists

Lead scientists for Treatments for Inflammation

Recent News

March 19th 2019

UPDATE - Arch Biopartners Receives Approval to Perform Phase I Clinical Trial for Metablok in Australia

February 7th 2019

Arch Biopartners Awarded NRC-IRAP Funding to Further Develop Metablok Drug Program

Arch Biopartners

Contact us

+1 647 428 7031
info@archbiopartners.com
545 King Street West
Toronto, Ontario
M5V 1M1 Canada

Copyright Arch BioPartners 2019. All Rights Reserved. Legal notices.

PAGE TOP | TYPE SIZE | | RESET

Reports and Filings